Manipulation of iron to determine survival: Competition between host and pathogen

Immunologic Research

Volumn 30, Issue 1, 2004, Pages 15-28

  Laham, Nihay ^a   Ehrlich, Rachel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

HFE; Host defense; Infections; Iron metabolism; Viral proteins

Indexed keywords

HFE PROTEIN; IRON; IRON REGULATORY FACTOR; VIRUS PROTEIN;

CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; EXTRACELLULAR SPACE; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IRON DEPLETION; IRON INTAKE; IRON METABOLISM; IRON STORAGE; IRON TRANSPORT; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; VIRUS PATHOGENESIS; VIRUS RESISTANCE; VIRUS VIRULENCE;

EID: 3242885124     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/ir:30:1:015     Document Type: Review

References (161)

1. Weinberg ED: The role of iron in protozoan and fungal infectious diseases. J Eukaryt Micro 1999;46:231-238.
2. Aisen P, Enns C, Wessling-Resnick M: Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol 2001;33:940-959.
3. Lieu PT, Heiskala M, Peterson PA, Yang Y: The roles of iron in health and disease. Mol Asp Med 2001;22:1-87.
4. van Vliet AH, Ketley JM, Park SF, Penn CW: The role of iron in Campylobacter gene regulation, metabolism and oxidative stress defense. FEMS Micro Rev 2002;26:173-186.
5. Boyer E, Bergevin I, Malo D, Gros P, Cellier MF: Acquisition of Mn(II) in addition to Fe(II) is required for full virulence of Salmonella enterica serovar Typhimurium. Infect Immun 2002;70:6032-6042.
6. Marx JJM: Iron and infection: competition between host and microbes for a precious element. Best Prac Res Clin Haemat 2002;15:411-426.
7. Braun V, Braun M: Iron transport and signaling in Escherichia coli. FEBS Lett 2002;529:78-85.
8. Braun V, Braun M: Active transport of iron and siderophore antibiotics. Curr Opin Micro 2002;5:194-201.
9. Brown JS, Holden DW: Iron acquisition by Gram-positive bacterial pathogens. Microb Infect 2002;4:1149-1156.
10. Visca P, Leoni L, Wilson MJ, Lamont IL: Iron transport and regulation, cell signalling and genomics: lessons from Escherichia coli and Pseudomonas. Mol Microb 2002;45:1177-1190.
11. Richardson DR, Ponka P: The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1997;1331:1-40.
12. Weinberg ED: Modulation of intramacrophage iron metabolism during microbial cell invasion. Microb Infect 2000;2:85-89.
13. Mikulits W, Schranzhofer M, Beug H, Mullner EW: Post-transcriptional control via iron-responsive elements: the impact of aberrations in hereditary disease. Mutat Res 1999;437:219-230.
14. Ehrlich R, Lemonnier FA: HFE-A novel nonclassical class I molecule that is involved in iron metabolism. Immunity 2000;13:585-588.
15. Parkkila S, Niemela O, Britton RS, Fleming RE, Waheed A, Bacon BR, Sly WS: Molecular aspects of iron absorption and HFE expression. Gastroenterology 2001;121:1489-1496.
16. Fleming RE, Sly WS: Mechanisms of iron accumulation in hereditary hemochromatosis. Ann Rev Physiol 2002;64:663-680.
17. Ganz T: The role of hepcidin in iron sequestration during infections and in the pathogenesis of anemia of chronic disease. Is Med Assoc J 2002;4:1043-1045.
18. Philpott CC: Molecular aspects of iron absorption: Insights into the role of HFE in hemochromatosis. Hepatology 2002;35:993-1001.
19. Pietrangelo A: Physiology of iron transport and the hemochromatosis gene. Am J Physiol Gastrointest Liver Physiol 2002;282:G403-414.
20. van Asbeck BS, Verbrugh HA, van Oost BA: Listeria monocytogenes meningitis and decreased phagocytosis assoicated with iron overload. Br Med J 1982;284:542-544.
21. Weinberg ED: Iron loading and disease surveillance. Emerg Infect Dis 1999;5:346-352.
22. Walker EM, Walker SM: Effects of iron overload on the immune system. Ann Clin Lab Sci 2000;30:354-365.
23. Lounis N, Truffot-Pernot C, Grosset J, Gordeuk VR, Boelaert JR: Iron and Mycobacterium tuberculosis infection. J Clin Virol 2001;20:123-126.
24. Barabino A: Helicobacter pylori-related iron deficiency anemia: a review. Helicobacter 2002;7:71-75.
25. Ward PP, Mendoza-Meneses M, Cunningham GA, Conneely OM: Iron status in mice carrying a targeted disruption of lactoferrin. Mol Cell Biol 2003;23:178-185.
26. Levay PF, Viljoen M: Lactoferrin: a general review. Haematologica 1995;80:252-267.
27. Guillen C, McInnes IB, Brock JH: Iron in synovial fluid. Removal by lactoferrin and relationship to iron regulatory protein (IRP) activity. Adv Exp Med Biol 1998;443:161-165.
28. Mason PL, Hermans JF, Schonne E: Lactoferrin, an iron-binding protein in neutrophil leukocytes. J Exp Med 1969;130:643-658.
29. Brock JH: The physiology of lactoferrin. Biochem Cell Biol 2002;80:1-6.
30. Potter BJ, Wang F: Molecular regulation of iron homeostasis and resistance to infection in alcoholics. Front Biosci 2002;7:d1396-1409.
31. Lonnerdal B, Iyer S: Lactoferrin: molecular structure and biological function. Ann Rev Nutrit 1995;15:93-110.
32. Aguila A, Herrera AG, Morrison D, Cosgrove B, Perojo A, Montesinos I, et al.: Bacteriostatic activity of human lactoferrin against Staphylococcus aureus is a function of its iron-binding properties and is not influenced by antibiotic resistance. FEMS Immun Med Micro 2001;31:145-152.
33. Schaible UE, Collins HL, Priem F, Kaufmann SH: Correction of the iron overload defect in beta-2-microglobulin knockout mice by lactoferrin abolishes their increased susceptibility to tuberculosis. J Exp Med 2002;196:1507-1513.
34. Ellison RT, Giehl TJ, LaForce EM: Damage of the outer membrane of enteric Gram-negative bacteria by lactoferrin and transferrin. Infect Immun 1988;56:2774-2781.
35. Ellison RT, Giehl TJ: Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest 1991;88:1080-1091.
36. Ward PP, Uribe-Luna S, Conneely OM: Lactoferrin and host defense. Biochem Cell Biol 2002;80:95102.
37. Singh PK, Parsek MR, Greenberg EP, Welsh MJ: A component of innate immunity prevents bacterial biofilm development. Nature 2002;417:552-555.
38. Ikeda M, Sugiyama K, Tanaka T, Tanaka K, Sekihara H, Shimotohno K, Kato N: Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem Biophys Res Commun 1998;245:549-553.
39. Tanaka K, Ikeda M, Nozaki A, Kato N, Tsuda H, Saito S, Sekihara H: Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. Jap J Cancer Res 1999;90:367-371.
40. van der Strate BW, Beljaars L, Molema G, Harmsen MC, Meijer DK: Antiviral activities of lactoferrin. Antiviral Res 2001;52:225-239.
41. Hara K, Ikeda M, Saito S, Matsumoto S, Numata K, Kato N, et al.: Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepat Res 2002;24:228.
42. Lin TY, Chu C, Chiu CH: Lactoferrin inhibits enterovirus 71 infection of human embryonal rhabdomyosarcoma cells in vitro. J Infect Dis 2002;186:1161-1164.
43. Brittenham GM, Weiss G, Brissot P, Laine F, Guillygomarc'h A, Guyader D, et al.: Clinical consequences of new insights in the pathophysiology of disorders of iron and heme metabolism. Hematology (Am Soc Hematol Educ Program) 2000;39-50.
44. Yang F, Liu XB, Quinones M, Melby PC, Ghio A, Haile DJ: Regulation of reticuloendothelial iron transporter MTP1 (Slc11a3) by inflammation. J Biol Chem 2002;277:39786-39791.
45. Konijn AM, Carmel N, Levy R, Hershko C: Ferritin synthesis in inflammation. II. Mechanism of increased ferritin synthesis. Br J Haematol 1981;49:361-370.
46. Byrd TF, Horwitz MA: Chloroquine inhibits the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. A potential new mechanism for the therapeutic effect of chloroquine against intracellular pathogens. J Clin Invest 1991;88:351-357.
47. Gebran SJ, Newton C, Yamamoto Y, Widen R, Klein TW, Friedman H: Macrophage permissiveness for Legionella pneumophila growth modulated by iron. Infect Immun 1994;62:564-568.
48. Newman SL, Gootee L, Brunner G, Deepe GS, Jr.: Chloroquine induces human macrophage killing of Histoplasma capsulatum by limiting the availability of intracellular iron and is therapeutic in a murine model of histoplasmosis. J Clin Invest 1994;93:1422-1429.
49. Savarino A, Calosso L, Piragino A, Martini C, Gennero L, Pescarmona GP, Pugliese A: Modulation of surface transferrin receptors in lymphoid cells de novo infected with human immunodeficiency virus type-1. Cell Biochem Funct 1999;17:47-55.
50. Lobmayr L, Sauer T, Killisch I, Schranzhofer M, Wilson RB, Ponka P, et al.: Transferrin receptor hyperexpression in primary erythroblasts is lost on transformation by avian erythroblastosis virus. Blood 2002;100:289-298.
51. Byrd TF, Horwitz MA: Interferon gamma-activated human monocytes downregulate transferrin receptors and inhibit the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. J Clin Invest 1989;83:1457-1465.
52. Byrd TF, Horwitz MA: Regulation of transferrin receptor expression and ferritin content in human mononuclear phagocytes. Coordinate upregulation by iron transferrin and downregulation by interferon gamma. J Clin Invest 1993;91:969-976.
53. Byrd TF, Horwitz MA: Lactoferrin inhibits or promotes Legionella pneumophila intracellular multiplication in nonactivated and interferon gamma-activated human monocytes depending upon its degree of iron saturation. Iron-lactoferrin and nonphysiologic iron chelates reverse monocyte activation against Legionella pneumophila. J Clin Invest 1991;88:1103-1112.
54. Torti SV, Kwak EL, Miller SC, Miller LL, Ringold GM, Myambo KB, et al.: The molecular cloning and characterization of murine ferritin heavy chain, a tumor necrosis factor-inducible gene. J Biol Chem 1988;263:12638-12644.
55. Wei Y, Miller SC, Tsuji Y, Torti SV, Torti FM: Interleukin 1 induces ferritin heavy chain in human muscle cells. Biochem Biophys Res Commun 1990;169:289-296.
56. Miller LL, Miller SC, Torti SV, Tsuji Y, Torti FM: Iron-independent induction of ferritin H chain by tumor necrosis factor. Proc Natl Acad Sci USA 1991;88:4946-4950.
57. Bourgeade MF, Silbermann F, Kuhn L, Testa U, Peschle C, Memet S, et al.: Post-transcriptional regulation of transferrin receptor mRNA by IFN gamma. Nucleic Acids Res 1992;20:2997-3003.
58. Rogers JT, Bridges KR, Durmowicz GP, Glass J, Auron PE, Munro HN: Translational control during the acute phase response. Ferritin synthesis in response to interleukin-1. J Biol Chem 1990;265:14572-14578.
59. Rogers JT, Andriotakis JL, Lacroix L, Durmowicz GP, Kasschau KD, Bridges KR: Translational enhancement of H-ferritin mRNA by interleukin-1 beta acts through 5′ leader sequences distinct from the iron responsive element. Nucleic Acids Res 1994;22:2678-2686.
60. Rogers JT: Ferritin translation by interleukin-land interleukin-6: the role of sequences upstream of the start codons of the heavy and light subunit genes. Blood 1996;87:2525-2537.
61. Govoni G, Gros P: Macrophage NRAMP1 and its role in resistance to microbial infections. Inflamm Res 1998;47:277-284.
62. Barton CH, Biggs TE, Baker ST, Bowen H, Atkinson PG: Nramp1: a link between intracellular iron transport and innate resistance to intracellular pathogens. J Leuk Biol 1999;66:757-762.
63. Blackwell JM, Searle S, Mohamad H, White JK: Divalent cation transport and susceptibility to infectious and autoimmune disease: continuaton of the Ity/Lsh/Bcg/Nramp1/Slc11a1 gene story. Immunol Lett 2003;85:197-203.
64. Govoni G, Vidal S, Cellier M, Lepage P, Malo D, Gros P: Genomic structure, promoter sequence, and induction of expression of the mouse Nramp1 gene in macrophages. Genomics 1995;27:9-19.
65. Govoni G, Gauthier S, Billia F, Iscove NN, Gros P: Cell-specific and inducible Nramp1 gene expression in mouse macrophages in vitro and in vivo. J Leuk Biol 1997;62:277-286.
66. Wyllie S, Seu P, Goss JA: The natural resistance-associated macrophage protein 1 Slc11a1 (formerly Nramp1) and iron metabolism in macrophages. Microb Infect 2002;4:351-359.
67. Gruenheid S, Pinner E, Desjardins M, Gros P: Natural resistance to infection with intracellular pathogens: the Nramp1 protein is recruited to the membrane of the phagosome. J Exp Med 1997;185:717-730.
68. Searle S, Bright NA, Roach TI, Atkinson PG, Barton CH, Meloen RH, Blackwell JM: Localisation of Nramp1 in macrophages: modulation with activation and infection. J Cell Sci 1998;111:2855-2866.
69. Kuhn DE, Baker BD, Lafuse WP, Zwilling BS: Differential iron transport into phagosomes isolated from the RAW264.7 macrophage cell lines transfected with Nramp1Gly169 or Nramp1Asp169. J Leuk Biol 1999;66:1113-1119.
70. Zwilling BS, Kuhn DE, Wikoff L, Brown D, Lafuse W: Role of iron in Nramp1-mediated inhibition of mycobacterial growth. Infect Immun 1999;67:1386-1392.
71. Hackam DJ, Rotstein OD, Zhang W, Gruenheid S, Gros P, Grinstein S: Host resistance to intracellular infection: mutation of natural resistance-associated macrophage protein 1 (Nramp1) impairs phagosomal acidification. J Exp Med 1998;188:351-364.
72. Biggs TE, Baker ST, Botham MS, Dhital A, Barton CH, Perry VH: Nramp1 modulates iron homoeostasis in vivo and in vitro: evidence for a role in cellular iron release involving de-acidification of intracellular vesicles. Eur J Immun 2001;31:2060-2070.
73. Gomes MS, Appelberg R: Evidence for a link between iron metabolism and Nramp1 gene function in innate resistance against Mycobacterium avium. Immunol 1998;95:165-168.
74. Cuellar-Mata P, Jabado N, Liu J, Furuya W, Finlay BB, Gros P, Grinstein S: Nramp1 modifies the fusion of Salmonella typhimurium-containing vacuoles with cellular endomembranes in macrophages. J Biol Chem 2002;277:2258-2265.
75. Frehel C, Canonne-Hergaux F, Gros P, De Chastellier C: Effect of Nramp1 on bacterial replication and on maturation of Mycobacterium avium-containing phagosomes in bone marrow-derived mouse macrophages. Cellular Microbiol 2002;4:541-556.
76. Gomes MS, Appelberg R: NRAMP1- or cytokine-induced bacteriostasis of Mycobacterium avium by mouse macrophages is independent of the respiratory burst. Microbiology 2002;148:3155-3160.
77. Zhong W, Lafuse W, Zwilling BS: Infection with Mycobacterium avium differentially regulates the expression of iron transport protein mRNA in murine peritoneal macrophages. Infect Immun 2001;69:6618-6624.
78. James SL: Role of nitric oxide in parasitic infections. Microbiol Rev 1995;59:533-547.
79. Brunet LR: Nitric oxide in parasitic infections. Int Immunopharm 2001;1:1457-1467.
80. Bogdan C: Nitric oxide and the regulation of gene expression. Trend Cell Biol 2001;11:66-75.
81. Eichenbaum Z, Muller E, Morse SA, Scott JR: Acquisition of iron from host proteins by the group A streptococcus. Infect Immun 1996;64:5428-5429.
82. Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, Porter JB: The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem 1996;271:20291-20299.
83. Lamarche N, Matton G, Massie B, Fontecave M, Atta M, Dumas F, et al.: Production of the R2 subunit of ribonucleotide reductase from herpes simplex virus with prokaryotic and eukaryotic expression systems: higher activity of R2 produced by eukaryotic cells related to higher iron-binding capacity. Biochemi J 1996;320:129-135.
84. Chabes A, Domkin V, Larsson G, Liu A, Graslund A, Wijmenga S, Thelander L: Yeast ribonucleotide reductase has a heterodimeric iron-radical-containing subunit. Proc Natl Acad Sci USA 2000;97:2474-2479.
85. Romeo AM, Christen L, Niles EG, Kosman DJ: Intracellular chelation of iron by bipyridyl inhibits DNA virus replication: ribonucleotide reductase maturation as a probe of intracellular iron pools. J Biol Chem 2001;276:24301-24308.
86. Boelaert JR, Weinberg GA, Weinberg ED: Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management. Infect Agent Dis 1996;5:36-46.
87. Weinberg ED: Development of clinical methods of iron deprivation for suppression of neoplastic and infectious diseases. Cancer Invest 1999;17:507-513.
88. Fernandez-Pol JA, Hamilton PD, Klos DJ: Essential viral and cellular zinc and iron containing metalloproteins as targets for novel antiviral and anticancer agents: implications for prevention and therapy of viral diseases and cancer. Anticancer Res 2001;21:931-957.
89. Simonart T, Boelaert JR, Mosselmans R, Andrei G, Noel JC, De Clercq E, Snoeck R: Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells. Gynecol Oncol 2002;85:95-102.
90. Dai Y, Gold B, Vishwanatha JK, Rhode SL: Mimosine inhibits viral DNA synthesis through ribonucleotide reductase. Virol 1994;205:210-216.
91. Cinatl J, Jr., Cinatl J, Rabenau H, Gumbel HO, Kornhuber B, Doerr HW: In vitro inhibition of human cytomegalovirus replication by desferrioxamine. Antiviral Res 1994;25:73-77.
92. Martelius T, Scholz M, Krogerus L, Hockerstedt K, Loginov R, Bruggeman C, et al.: Antiviral and immunomodulatory effects of desferrioxamine in cytomegalovirus-infected rat liver allografts with rejection. Transplant 1999;68:1753-1761.
93. Savarino A, Pescarmona GP, Boelaert JR: Iron metabolism and HIV infection: reciprocal interactions with potentially harmful consequences? Cell Biochem Funct 1999;17:279-287.
94. Gordeuk VR, Delanghe JR, Langlois MR, Boelaert JR: Iron status and the outcome of HIV infection: an overview. J Clin Virol 2001;20:111-115.
95. van Asbeck BS, Georgiou NA, van der Bruggen T, Oudshoorn M, Nottet HS, Marx JJ: Anti-HIV effect of iron chelators: different mechanisms involved. J Clin Virol 2001;20:141-147.
96. Georgiou NA, van der Bruggen T, Oudshoorn M, Nottet HS, Marx JJ, van Asbeck BS: Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin. J Infect Dis 2000;181:484-490.
97. Georgiou NA, van der Bruggen T, Oudshoorn M, Hider RC, Marx JJ, van Asbeck BS: Human immunodeficiency virus type 1 replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and the onset of apoptosis. Eur J Clin Invest 2002;32 Suppl 1:91-96.
98. Sappey C, Boelaert JR, Legrand-Poels S, Forceille C, Favier A, Piette J: Iron chelation decreases NF-kappa B and HIV type 1 activation due to oxidative stress. AIDS Res Hum Retrovirus 1995;11:1049-1061.
99. Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, et al.: Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995;22:449-456.
100. Ikura Y, Morimoto H, Johmura H, Fukui M, Sakurai M: Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am J Gastroenterol 1996;91:1367-1373.
101. Roeckel IE: Commentary: Iron metabolism in hepatitis C infection. Ann Clin Lab Sci 2000;30:163-165.
102. Fargion S, Fracanzani AL, Rossini A, Borzio M, Riggio O, Belloni G, et al.: Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. [comment] Am J Gastroenterol 2002;97:1204-1210.
103. Piperno A, Vergani A, Malosio I, Parma L, Fossati L, Ricci A, et al.: Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations. Hepatology 1998;28:1105-1109.
104. Bonkovsky HL: Iron as a comorbid factor in chronic viral hepatitis. [comment]. Am J Gastroenterol 2002;97:1-4.
105. Martinelli AL, Franco RF, Villanova MG, Figueiredo JF, Secaf M, Tavella MH, et al.: Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection? Acta Haematol 2000;102:152-156.
106. Bonkovsky HL, Troy N, McNeal K, Banner B, Sharma A, Obando J, et al.: Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. Hepatol 2002;37:848-854.
107. Diwakaran HH, Befeler AS, Britton RS, Brunt EM, Bacon BR: Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J Hepatol 2002;36:687-691.
108. Tung BY, Emond MJ, Bronner MP, Raaka SD, Cotler SJ, Kowdley KV: Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 2003;124:318-326.
109. Van Vlierberghe H, Delanghe JR, De Bie S, Praet M, De Paepe A, Messiaen L, et al.: Association between Cys282Tyr missense mutation and haptoglobin phenotype polymorphism in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2001;13:1077-1081.
110. Thorburn D, Curry G, Spooner R, Spence E, Oien K, Halls D, et al.: The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002;50:248-252.
111. Tsuji Y, Kwak E, Saika T, Torti SV, Torti FM: Preferential repression of the H subunit of ferritin by adenovirus E1A in NIH-3T3 mouse fibroblasts. J Biol Chem 1993;268:7270-7275.
112. Tsuji Y, Akebi N, Lam TK, Nakabeppu Y, Torti SV, Torti FM: FER-1, an enhancer of the ferritin H gene and a target of E1A-mediated transcriptional repression. Mol Cell Biol 1995;15:5152-5164.
113. Tsuji Y, Moran E, Torti SV, Torti FM: Transcriptional regulation of the mouse ferritin H gene. Involvement of p300/CBP adaptor proteins in FER-1 enhancer activity. J Biol Chem 1999;274:7501-7507.
114. Bevilacqua MA, Faniello MC, D'Agostino P, Quaresima B, Tiano MT, Pignata S, et al.: Transcriptional activation of the H-ferritin gene in differentiated Caco-2 cells parallels a change in the activity of the nuclear factor Bbf. Biochem J 1995;311:769-773.
115. Bevilacqua MA, Faniello MC, Quaresima B, Tiano MT, Giuliano P, Feliciello A, et al.: A common mechanism underlying the E1A repression and the cAMP stimulation of the H ferritin transcription. J Biol Chem 1997;272:20736-20741.
116. Torti FM, Torti SV: Regulation of ferritin genes and protein. Blood 2002;99:3505-3516.
117. Orino K, Tsuji Y, Torti FM, Torti SV: Adenovirus E1A blocks oxidant-dependent ferritin induction and sensitizes cells to pro-oxidant cytotoxicity. FEBS Lett 1999;461:334-338.
118. Tsuji Y, Ayaki H, Whitman SP, Morrow CS, Torti SV, Torti FM: Coordinate transcriptional and translational regulation of ferritin in response to oxidative stress. Mol Cell Biol 2000;20:5818-5827.
119. Ben-Arieh SV, Zimerman B, Smorodinsky NI, Yaacubovicz M, Schechter C, Bacik I, et al.: Human cytomegalovirus protein US2 interferes with the expression of human HFE, a nonclassical class I major histocompatibility complex molecule that regulates iron homeostasis. J Virol 2001;75:10557-10562.
120. Vahdati-Ben Arieh S, Laham N, Schechter C, Yewdell JW, Coligan JE, Ehrlich R: A single viral protein HCMV US2 affects antigen presentation and intracellular iron homeostasis by degradation of classical HLA class I and HFE molecules. Blood 2003;101:2858-2864.
121. Jones TR, Hanson LK, Sun L, Slater JS, Stenberg RM, Campbell AE: Multiple independent loci within the human cytomegalovirus unique short region downregulate expression of major histocompatibility complex class I heavy chains. J Virol 1995;69:4830-4841.
122. Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL: The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 1996;84:769-779.
123. Jones TR, Sun L: Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains. J Virol 1997;71:2970-2979.
124. Machold RP, Wiertz EJ, Jones TR, Ploegh HL: The HCMV gene products US11 and US2 differ in their ability to attack allelic forms of murine major histocompatibility complex (MHC) class I heavy chains. J Exp Med 1997;185:363-366.
125. Farrell HE, Davis-Poynter NJ: From sabotage to camouflage: viral evasion of cytotoxic T lymphocyte and natural killer cell-mediated immunity. Sem Cell Develop Biol 1998;9:369-378.
126. Mocarski ES, Jr.: Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trend Microbiol 2002;10:332-339.
127. Vossen MT, Westerhout EM, Soderberg-Naucler C, Wiertz EJ: Viral immune evasion: a masterpiece of evolution. Immunogenetics 2002;54:527-542.
128. Tomazin R, Boname J, Hegde NR, Lewinsohn DM, Altschuler Y, Jones TR, et al.: Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Nat Med 1999;5:1039-1043.
129. Chevalier MS, Daniels GM, Johnson DC: Binding of human cytomegalovirus US2 to major histocompatibility complex class I and II proteins is not sufficient for their degradation. [Erratum appears in J Virol 2002 Dec;76(24):13126.] J Virol 2002;76:8265-8275.
130. Wiertz EJ, Tortorella D, Bogyo M, Yu J, Mothes W, Jones TR, et al.: Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction [see comments]. Nature 1996;384:432-438.
131. Gross CN, Irrinki A, Feder JN, Enns CA: Co-trafficking of HFE, a nonclassical major histocompatibility complex class I protein, with the transferrin receptor implies a role in intracellular iron regulation. J Biol Chem 1998;273:22068-22074.
132. Corsi B, Levi S, Cozzi A, Corti A, Altimare D, Albertini A, Arosio P: Overexpression of the hereditary hemochromatosis protein, HFE, in HeLa cells induces and iron-deficient phenotype. FEBS Lett 1999;460:149-152.
133. Riedel HD, Muckenthaler MU, Gehrke SG, Mohr I, Brennan K, Herrmann T, et al.: HFE downregulates iron uptake from transferrin and induces iron-regulatory protein activity in stably transfected cells. Blood 1999;94:3915-3921.
134. Roy CN, Penny DM, Feder JN, Enns CA: The hereditary hemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells. J Biol Chem 1999;274:9022-9028.
135. Ramalingam TS, West AP, Jr., Lebron JA, Nangiana JS, Hogan TH, Enns CA, Bjorkman PJ: Binding to the transferrin receptor is required for endocytosis of HFE and regulation of iron homeostasis. Nat Cell Biol 2000;2:953-957.
136. Arredondo M, Munoz P, Mura CV, Nunez MT: HFE inhibits apical iron uptake by intestinal epithelial (Caco-2) cells. FASEB J 2001;15:1276-1278.
137. Feeney GP, Worwood M: The effects of wild-type and mutant HFE expression upon cellular iron uptake in transfected human embryonic kidney cells. Biochim Biophys Acta 2001;1538:242-251.
138. Roy CN, Blemings KP, Deck KM, Davies PS, Anderson EL, Eisenstein RS, Enns CA: Increased IRP1 and IRP2 RNA binding activity accompanies a reduction of the labile iron pool in HFE-expressing cells. J Cell Physiol 2002;190:218-226.
139. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al.: A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis [see comments]. Nat Genet 1996;13:399-408.
140. Feder JN, Tsuchihashi Z, Irrinki A, Lee VK, Mapa FA, Morikang E, et al.: The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem 1997;272:14025-14028.
141. Waheed A, Parkkila S, Zhou XY, Tomatsu S, Tsuchihashi Z, Feder JN, et al.: Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci USA 1997;94:12384-12389.
142. Parkkila S, Waheed A, Britton RS, Bacon BR, Zhou XY, Tomatsu S, et al.: Association of the transferrin receptor in human placenta with HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci USA 1997;94:13198-13202.
143. Feder JN, Penny DM, Irrinki A, Lee VK, Lebron JA, Watson N, et al.: The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 1998;95:1472-1477.
144. Salter-Cid L, Brunmark A, Li Y, Leturcq D, Peterson PA, Jackson MR, Yang Y: Transferrin receptor is negatively modulated by the hemochromatosis protein HFE: implications for cellular iron homeostasis. Proc Natl Acad Sci USA 1999;96:5434-5439.
145. Lebron JA, West AP, Jr, Bjorkman PJ: The hemochromatosis protein HFE competes with transferrin for binding to the transferrin receptor. J Mol Biol 1999;294:239-245.
146. Ikuta K, Fujimoto Y, Suzuki Y, Tanaka K, Saito H, Ohhira M, et al.: Overexpression of hemochromatosis protein, HFE, alters transferrin recycling process in human hepatoma cells. Biochim Biophys Acta 2000;1496:221-231.
147. Kowdley KV, Tavill AS: An "ironic" case of mistaken identity? Hepatology 1992;16:500-501.
148. Gerhard GS, Ten Elshof AE, Chorney MJ: Hereditary haemochromatosis as an immunological disease. Br J Haematol 1998;100:247-255.
149. Pietrangelo A, Casalgrandi G, Quaglino D, Gualdi R, Conte D, Milani S, et al.: Duodenal ferritin synthesis in genetic hemochromatosis. Gastroenterology 1995;108:208-217.
150. Simpson RJ, Debnam ES, Laftah AH, Solanky N, Beaumont NJ, Bahram S, et al.: Duodenal non-heme iron content correlates with iron stores in mice, but the relationship is altered by Hfe gene knock-out. Blood 2003;101:3316-3318.
151. Trinder D, Olynyk JK, Sly WS, Morgan EH: Iron uptake from plasma transferrin by the duodenum is impaired in the Hfe knockout mouse. Proc Natl Acad Sci USA 2002;99:5622-5626.
152. Powell LW, Campbell CB, Wilson E: Intestinal mucosal uptake of iron and iron retention in idiopathic haemochromatosis as evidence for a mucosal abnormality. Gut 1970;11:727-731.
153. Bahram S, Gilfillan S, Kuhn LC, Moret R, Schulze JB, Lebeau A, Schumann K: Experimental hemochromatosis due to MHC class I HFE deficiency: immune status and iron metabolism. Proc Natl Acad Sci USA 1999;96:13312-13317.
154. Waheed A, Parkkila S, Saarnio J, Fleming RE, Zhou XY, Tomatsu S, et al.: Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum. Proc Natl Acad Sci USA 1999;96:1579-1584.
155. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, Vaulont S: Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. [comment]. Proc Natl Acad Sci USA 2001;98:8780-8785.
156. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, et al.: Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002;99:4596-4601.
157. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al.: The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110:1037-1044.
158. Fletcher LM, Halliday JW: Haemochromatosis: understanding the mechanism of disease and implications for diagnosis and patient management following the recent cloning of novel genes involved in iron metabolism. J Intern Med 2002;251:181-192.
159. Drakesmith H, Townsend A: The structure and function of HFE. Bioessays 2000;22:595-598.
160. Montosi G, Paglia P, Garuti C, Guzman CA, Bastin JM, Colombo MP, Pietrangelo A: Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis. Blood 2000;96:1125-1129.
161. Drakesmith H, Sweetland E, Schimanski L, Edwards J, Cowley D, Ashraf M, et al.: The hemochromatosis protein HFE inhibits iron export from macrophages. Proc Natl Acad Sci USA 2002;99:15602-15607.